To include your compound in the COVID-19 Resource Center, submit it here.

A new pocket for D4

Crystal structure paves way to dopamine D4 receptor-selective agonists

The early promise of the dopamine D4 receptor as a therapeutic target for psychiatric disorders hasn’t been borne out because of the difficulty of producing sufficiently selective compounds. Last month in Science, a collaboration between UNC Chapel Hill and UCSF united crystallography and in silico drug discovery to find a selective D4 agonist that could spur new cognitive therapies.

The study was led by Bryan Roth, a pharmacology professor at University of North Carolina at

Read the full 743 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers